中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
23期
67-70
,共4页
复方丹参注射液%新生儿%缺氧缺血性脑病%预防
複方丹參註射液%新生兒%缺氧缺血性腦病%預防
복방단삼주사액%신생인%결양결혈성뇌병%예방
Compound Salvia Miltiorrhiza Injection%Newborn%Hypoxic ischemic encephalopathy%Prevention
目的：探讨研究复方丹参注射液预防新生儿缺氧缺血性脑病(HIE)的临床疗效。方法将符合标准的180例具有HIE病因的新生儿随机分成观察组(90例)和对照组(90例)，观察组患儿在正常护理的同时给予静脉滴注复方丹参注射液预防治疗，对照组患儿仅给予正常护理。结果观察组患儿HIE的轻度、重度以及总发生率分别为21.1%、10.0%以及46.7%，显著性低于对照组患儿的34.4%、21.1%以及77.8%(P<0.05)。观察组治疗后肌酸激酶与肌酸酶脑型同工酶水平分别为(1479.4±214.7)、(167.3±45.6)U/L，显著性低于对照组[(1879.0±478.6)、(233.1±50.0)U/L](P<0.05)。在治疗后9个月与12个月，观察组Gesell评分≤75分的患儿显著低于对照组(P<0.05)；观察组Gesell评分≥86分的患儿显著高于对照组(P<0.05)。两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。结论使用复方丹参注射液能够有效地预防性治疗新生儿HIE，减少具有HIE病因的新生儿HIE的发病，促进新生儿后期的正常发育，同时并不增加不良反应的发生率，安全可行，值得在临床上推广使用。
目的：探討研究複方丹參註射液預防新生兒缺氧缺血性腦病(HIE)的臨床療效。方法將符閤標準的180例具有HIE病因的新生兒隨機分成觀察組(90例)和對照組(90例)，觀察組患兒在正常護理的同時給予靜脈滴註複方丹參註射液預防治療，對照組患兒僅給予正常護理。結果觀察組患兒HIE的輕度、重度以及總髮生率分彆為21.1%、10.0%以及46.7%，顯著性低于對照組患兒的34.4%、21.1%以及77.8%(P<0.05)。觀察組治療後肌痠激酶與肌痠酶腦型同工酶水平分彆為(1479.4±214.7)、(167.3±45.6)U/L，顯著性低于對照組[(1879.0±478.6)、(233.1±50.0)U/L](P<0.05)。在治療後9箇月與12箇月，觀察組Gesell評分≤75分的患兒顯著低于對照組(P<0.05)；觀察組Gesell評分≥86分的患兒顯著高于對照組(P<0.05)。兩組患兒不良反應髮生率比較差異無統計學意義(P>0.05)。結論使用複方丹參註射液能夠有效地預防性治療新生兒HIE，減少具有HIE病因的新生兒HIE的髮病，促進新生兒後期的正常髮育，同時併不增加不良反應的髮生率，安全可行，值得在臨床上推廣使用。
목적：탐토연구복방단삼주사액예방신생인결양결혈성뇌병(HIE)적림상료효。방법장부합표준적180례구유HIE병인적신생인수궤분성관찰조(90례)화대조조(90례)，관찰조환인재정상호리적동시급여정맥적주복방단삼주사액예방치료，대조조환인부급여정상호리。결과관찰조환인HIE적경도、중도이급총발생솔분별위21.1%、10.0%이급46.7%，현저성저우대조조환인적34.4%、21.1%이급77.8%(P<0.05)。관찰조치료후기산격매여기산매뇌형동공매수평분별위(1479.4±214.7)、(167.3±45.6)U/L，현저성저우대조조[(1879.0±478.6)、(233.1±50.0)U/L](P<0.05)。재치료후9개월여12개월，관찰조Gesell평분≤75분적환인현저저우대조조(P<0.05)；관찰조Gesell평분≥86분적환인현저고우대조조(P<0.05)。량조환인불량반응발생솔비교차이무통계학의의(P>0.05)。결론사용복방단삼주사액능구유효지예방성치료신생인HIE，감소구유HIE병인적신생인HIE적발병，촉진신생인후기적정상발육，동시병불증가불량반응적발생솔，안전가행，치득재림상상추엄사용。
Objective To integrative clinical efficacy of Compound Salvia Miltiorrhiza Injection in prevention of neona-tal hypoxic ischemic encephalopathy (HIE). Methods 180 newborns with HIE causes were randomly divided into ob-served group (90 cases) and control group (90 cases), newborns in observed group received the treatment of normal nursing with intravenous drip of Compound Salvia Miltiorrhiza Injection, while the control group received the treatment of normal nursing only. Results The mild, severe and total incidence of HIE in observed group were 21.1%, 10.0% and 46.7%, which were significantly lower than those in control group which were 34.4%, 21.1% and 77.8% (P<0.05). Af-ter the treatment, the CK and CK-BB in observed group were (1479.4±214.7), (167.3±45.6) U/L, which were signifi-cantly lower than those in control group [(1879.0±478.6), (233.1±50.0) U/L] (P< 0.05). In 9 months and 12 months af-ter treatment, the Gesell score ≤75 points was significantly lower than that in control group (P<0.05) and the Gesell score≥86 points was significantly higher than that in control group (P<0.05). There was no significant difference in adverse reaction between the two groups (P>0.05). Conclusion Compound Salvia Miltiorrhiza Injection has good pre-vention of HIE and can promote the normal development of newborn in later. This treatment is safe and feasible and it is worthy of promotion in clinic.
